An observational study in Non Small Cell Lung Cancer and Small-cell Lung Cancer, sponsored by Mahmut Gumus. Active, not recruiting at 39 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by Mahmut Gumus · Observational
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up.
These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 6,000 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →This is the only study on the registry with Mahmut Gumus as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Six thousands REGISTURK patients treated at 42 study sites (university hospitals, education and research hospitals and private hospital-based oncology practices).REGISTURK sites will be selected in accordance with patients load, hospital type and geographical distribution. All patients diagnosed with NSCLC or SCLC at selected centers will be enrolled consecutively throughout the study period. All patients diagnosed with lung cancer who receive treatment or who are followed with the best supportive care approach or refuse treatment will be recorded. All approaches in this regard will be determined and the reasons will be examined. Adult male and female patients with non-small cell (early, locally advanced or metastatic) or small cell will be considered "REGISTURK-LUNG patients"
Exclusion Criteria:
Frequency of molecular/mutational analysis
To collect data on the frequency of molecular/mutational biomarker testing
Time frame: throughout of treatment, 36 months
Type of molecular/mutational analysis
To collect data on the type of molecular/mutational biomarker testing
Time frame: throughout of treatment, 36 months
Type of treatment
To describe systemic treatments and sequential treatments applied in real-life practice.
Time frame: throughout of treatment, 36 months
The Rate of Response Rate
Response rate
Time frame: throughout of treatment, 36 months
Progression free survival time
Progression free survival
Time frame: throughout of treatment, 36 months
Overall survival time
Overall survival
Time frame: throughout of treatment, 36 months
The frequency of comorbidities
Comorbidities rate
Time frame: throughout of treatment, 36 months
Advers events rate
Advers events
Time frame: throughout of treatment, 36 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.